523 related articles for article (PubMed ID: 12429580)
21. Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway.
Branka JE; Vallette G; Jarry A; Laboisse CL
Biochem J; 1997 Apr; 323 ( Pt 2)(Pt 2):521-4. PubMed ID: 9163347
[TBL] [Abstract][Full Text] [Related]
22. Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery.
Brunner F; Schmidt K; Nielsen EB; Mayer B
J Pharmacol Exp Ther; 1996 Apr; 277(1):48-53. PubMed ID: 8613957
[TBL] [Abstract][Full Text] [Related]
23. NO-donors, part 9 : diazeniumdiolates inhibit human platelet aggregation and induce a transient vasodilatation of porcine pulmonary arteries in accordance with the NO-releasing rates.
Abuo-Rahma Gel D; Horstmann A; Radwan MF; El-Emam A; Glusa E; Lehmann J
Eur J Med Chem; 2005 Mar; 40(3):281-7. PubMed ID: 15725497
[TBL] [Abstract][Full Text] [Related]
24. Failure of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to inhibit soluble guanylyl cyclase in rat ventricular cardiomyocytes.
Wegener JW; Closs EI; Förstermann U; Nawrath H
Br J Pharmacol; 1999 Jun; 127(3):693-700. PubMed ID: 10401560
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide directly inhibits ghrelin-activated neurons of the arcuate nucleus.
Riediger T; Giannini P; Erguven E; Lutz T
Brain Res; 2006 Dec; 1125(1):37-45. PubMed ID: 17109829
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
[TBL] [Abstract][Full Text] [Related]
27. Effects of nitric oxide donors and inhibitors of nitric oxide signalling on endothelin- and serotonin-induced contractions in human placental arteries.
Sand AE; Andersson E; Fried G
Acta Physiol Scand; 2002 Mar; 174(3):217-23. PubMed ID: 11906320
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones.
Fernández-Tomé P; Lizasoain I; Leza JC; Lorenzo P; Moro MA
Neuropharmacology; 1999 Sep; 38(9):1307-15. PubMed ID: 10471084
[TBL] [Abstract][Full Text] [Related]
29. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase.
Roger S; Paysant J; Badier-Commander C; Cordi A; Verbeuren TJ; Félétou M
Vascul Pharmacol; 2010; 53(5-6):281-7. PubMed ID: 20933607
[TBL] [Abstract][Full Text] [Related]
30. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of platelet adhesion to collagen by cGMP-elevating agents.
Wu CC; Ko FN; Teng CM
Biochem Biophys Res Commun; 1997 Feb; 231(2):412-6. PubMed ID: 9070290
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets.
Tsikas D; Ikic M; Tewes KS; Raida M; Frölich JC
FEBS Lett; 1999 Jan; 442(2-3):162-6. PubMed ID: 9928994
[TBL] [Abstract][Full Text] [Related]
34. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.
Gudmundsdóttir IJ; McRobbie SJ; Robinson SD; Newby DE; Megson IL
Biochem Biophys Res Commun; 2005 Nov; 337(1):382-5. PubMed ID: 16185664
[TBL] [Abstract][Full Text] [Related]
35. Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation.
Tseng CM; Tabrizi-Fard MA; Fung HL
J Pharmacol Exp Ther; 2000 Feb; 292(2):737-42. PubMed ID: 10640313
[TBL] [Abstract][Full Text] [Related]
36. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.
Roger S; Badier-Commander C; Paysant J; Cordi A; Verbeuren TJ; Félétou M
Br J Pharmacol; 2010 Nov; 161(5):1044-58. PubMed ID: 20977455
[TBL] [Abstract][Full Text] [Related]
37. Formation of releasable NO stores by S-nitrosoglutathione in arteries exhibiting tolerance to glyceryl-trinitrate.
Sarr M; Lobysheva I; Diallo AS; Stoclet JC; Schini-Kerth VB; Muller B
Eur J Pharmacol; 2005 Apr; 513(1-2):119-23. PubMed ID: 15878716
[TBL] [Abstract][Full Text] [Related]
38. Nitric oxide inhibits capacitative Ca2+ entry by suppression of mitochondrial Ca2+ handling.
Thyagarajan B; Malli R; Schmidt K; Graier WF; Groschner K
Br J Pharmacol; 2002 Nov; 137(6):821-30. PubMed ID: 12411413
[TBL] [Abstract][Full Text] [Related]
39. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
[TBL] [Abstract][Full Text] [Related]
40. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.
Crane MS; Rossi AG; Megson IL
Br J Pharmacol; 2005 Mar; 144(6):849-59. PubMed ID: 15685209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
